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Rapid and Simultaneous Determination of
Acetylsalicylic Acid, Paracetamol, and
Their Degradation and Toxic Impurity Products
by HPLC in Pharmaceutical Dosage Forms
Aims: Determinations of drug impurity and drug degradation products are very important from both
pharmacological and toxicological perspectives. Establishment of monitoring methods for impurities and
degradation products during pharmaceutical development is necessary because of their potential toxicity. The
aim of this study was to develop a rapid and simultaneous determination method for paracetamol and
acetylsalicylic acid (ACA) and their degradation and toxic impurity products by high performance liquid
chromatography (HPLC) in pharmaceutical dosage forms.
Materials and Methods: A reverse phase (RP)-HPLC method for the simultaneous analysis of paracetamol,
ACA, and ascorbic acid and their degradation and impurity products such as salicylic acid (SA) and pchloroacetanilide was developed and applied to the determination of these compounds in commercial dosage
forms. These compounds were well separated on a Bondapak C18 reverse phase column using a mobile phase
consisting of a mixture of methanol: water (35:65; v/v) adjusted to pH 3.1 with 10% orthophosphoric acid
at a flow rate of 1.8 ml.min-1 and the effluent was monitored at 235 nm. Sulfamethoxazole was used as an
internal standard.
Results: The proposed method was linear in the ranges of 0.5-4.0, 0.75-6.0, 0.75-6.0, 1.0-12.0 and 1.0-1
12.0 µg m1 for paracetamol, ACA, ascorbic acid, SA and p-chloroacetanilide, respectively. Relative standard
deviations for repeatability, reproducibility and recovery were below 2%.
Conclusions: In this study, a RP-HPLC method, which is simple, rapid and does not require any separation
step for each drug, was successfully applied for the quantitative assay of paracetamol, ACA, ascorbic acid, and
their degradation and toxic impurity products in commercial tablet dosage forms.
Key Words: Degradation and impurity products, acetylsalicylic acid, paracetamol, salicylic acid, pchloroacetanilide, HPLC

Baz› Farmasötik Dozaj ﬁekillerinde Bulunan Asetil Salisilik Asit,
Parasetamol ve Bunlar›n Y›k›lma/Kat›ﬂ›kl›k Ürünlerinin H›zl› ve
Eﬂzamanl› Bir HPLC Yöntemi ile Saptanmas›
Amaç: Ticari farmasötik ﬂekiller içinde bulunan ilaç moleküllerininin ve safl›klar›n›n saptanmas›, toksikolojik ve
farmakolojik bak›mdan önemlidir. Farmasötik ﬂekillerin haz›rlanmas› s›ras›nda safl›k ve ilgili bozulma
ürünlerinin izlenebilmesi için ileri metotlara ihtiyaç vard›r. Bu çal›ﬂman›n amac› farmasötik dozaj ﬂekillerinde
parasetamol, asetil salisilik asit (ASA) ve bunlar›n y›k›lma/kat›ﬂ›kl›k ürünlerinin HPLC yöntemi ile h›zl› ve eﬂzamanl› olarak saptanmas›d›r.
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Yöntemler: Ticari dozaj ﬂekillerindeki parasetamol, ASA, askorbik asit ve bu preparatlarda y›k›lma ya da
kat›ﬂ›kl›k ürünü olarak bulunan salisilik asit ve p-kloroasetanilitin saptanmas› için bir reverse faz HPLC (yüksek
performansl› s›v› kromatografisi) metodu geliﬂtirilmiﬂtir. Bu bileﬂikler C18 ters faz kolon kullan›larak mobil faz›
metanol:su (35:65;v/v) kar›ﬂ›m›ndan oluﬂan pH’s› % 10’luk ortofosforik asitle 3.1’e ayarlanan ak›ﬂ h›z› 1.8
ml/dakika ve 235 nm’ de izlenmiﬂtir. Sülfametaksazol internal standart olarak kullan›lm›ﬂt›r.
Bulgular: Yeni geliﬂtirilen HPLC metodu, parasetamol, asetilsalisilik asid, askorbik asid, salisilik asid ve pkloroasetanilit için s›ras›yla 0.5-4.0, 0.75-6.0, 0.75-6.0, 1.0-12.0 ve 1.0-12.0 mg/ml aral›klar›nda do¤rusal
bulunmuﬂtur. Tekrarlanabilirlik ve geri kazan›m için göreceli standart sapma % 2’nin alt›nda olarak
saptanm›ﬂt›r.
Sonuç: Bu çal›ﬂmada geliﬂtirilen RP-HPLC metodu, parasetamol, ASA, askorbik asit içeren farmasötik dozaj
ﬂekillerinde ilaç molekülleri ve bunlar›n bozulma ve/veya kat›ﬂ›kl›k (safs›zl›k) ürünleri için h›zl›, basit ve herhangi
bir ön ekstraksiyon gerektirmeyen ve baﬂar›yla uygulanabilecek bir yöntemdir
Anahtar Sözcükler: Y›k›lma ve Kat›ﬂ›kl›k Ürünleri, Asetilsalisilik Asit, Parasetamol, Salisilik Asit , pkloroasetanilit, HPLC
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Introduction
An impurity in a drug is any chemical component of
the drug substance that has no chemical entity defined as
a drug substance. The safety of a drug is dependent not
only on the toxicological properties of the active
substance itself, but also on its pharmaceutical impurities,
which consist of reaction by-products generated during
synthesis of drug substances (namely, active
pharmaceutical ingredients) and degradation products
formed during the formulation manufacturing process
and/or storage of drug substances or formulated
products. Pharmaceutical impurities, also referred to as
‘related substances’, could often have pharmacological or
toxicological relevance. Therefore, the presence of such
impurities and their levels in products are indicators of
product quality, which can impose a risk to patient safety
(1-3).
Acetylsalicylic acid (ACA) has analgesic, antiinflammatory and antipyretic properties. It is used for
relief of less severe types of pain such as headache,
dysmenorrhea, myalgia and toothache (4,5). However,
intentional or accidental ingestion of salicylates represents
a major poisoning problem (6). Most salicylate poisoning
involves the use of aspirin or ACA. Paracetamol (PAR) is
also an analgesic and antipyretic drug but lacks antiinflammatory properties (4,5). PAR is hepatotoxic and
nephrotoxic in humans and experimental animals in toxic
doses. PAR is one of the most common causes of
morbidity and mortality in drug-poisoning cases (7-10).
Ascorbic acid (AA) is a water-soluble vitamin. It is
essential for the synthesis of collagen and intracellular
material (4,5). PAR, ACA and AA are active compounds
that are widely used and frequently combined in
pharmaceuticals. A combination of PAR, ACA and AA has
been used in many formulations in the market.
Various analytical techniques for the determination of
PAR, ACA and AA exist individually or in combination
including
liquid
chromatography
(11-18),
spectrophotometry (11,18-22), spectrofluorometry
(23), FT-Raman spectroscopy (24), and near infrared
spectroscopy (25). High performance liquid
chromatography (HPLC) methods are useful for
simultaneous determination of drugs and their
degradation and impurity products in pharmaceutical
dosage forms. Since HPLC has been used widely in
routine analysis, it is important to develop a HPLC
method that is thoroughly validated (26-28).
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To our knowledge, there is no information in the
literature and pharmacopoeias about the simultaneous
determination of PAR, ACA, AA and their degradation and
impurity products, namely salicylic acid (SA) and pchloroacetanilide (PCA), in bulk form and pharmaceutical
formulations.
An ideal stability-indicating HPLC method should be
able to resolve the main compounds of drug degradation
and impurity products. Therefore, we have developed a
rapid, accurate, reproducible and validated method for
simultaneous determination of PAR, ACA and AA for their
impurity and degradation products, namely SA and PCA.

Materials and Methods
Apparatus
A liquid chromatographic system consisted of a
Waters Isocratic LC pump 510, with an automatic sample
injection system (Waters 717 plus Autosampler),
equipped with a Waters 996 photodiode array detector.
Chromatographic separation was performed on a
Bondapak C18 reverse phase column packed with 10 mm
dimethyloctadecyl bonded amorphous silica (300 mm ×
3.9 mm). All solutions were filtered through 0.45 mm
Millipore filter prior to use and degassed using an
ultrasonic bath.
Chromatographic Conditions
The mobile phase consisted of a mixture of methanol:
water (35:65; v/v) adjusted to pH 3.1 with 10%
orthophosphoric acid. The mobile phase was prepared
daily, filtered, and sonicated prior to use. All analyses
were performed under isocratic conditions at a flow rate
-1
of 1.8 ml min and the effluent was monitored at 235
nm. 10 µl of each solution was injected and
chromatograms were recorded.
Chemicals and Reagents
PAR, ACA, AA, SA and PCA were supplied from
Sigma. Methanol was of HPLC grade, purchased from
Merck (Darmstadt, Germany). All other chemicals were
commercial analytical reagent grade. Double distilled
water was used for preparing mobile phase solutions.
Standard Stock Solution
Stock solutions were prepared separately by
dissolving PAR, ACA, AA, SA and PCA in mobile phase to
-1
obtain concentrations of 1.0, 1.5, 1.5, and 1.0 mg ml ,
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respectively. The standard solutions of PAR, ACA, AA, SA
-1
and PCA containing a fixed concentration (8 µg ml ) of
sulfamethoxazole (internal standard) (SMZ) were
prepared in mobile phase by varying the different
concentrations in the ranges of 0.5-4.0, 0.75-6.0, 0.75-1
6.0, 1.0-12.0 and 1.0-12.0 µg ml , respectively.
Triplicate 10 µl injections were made for each
concentration and the peak area ratio of each drug to the
internal standard was plotted against the corresponding
concentration to obtain calibration graph.
The proposed method was validated, and precision
[reported as the relative standard deviation (RSD %)],
linearity (evaluated by regression equations), detection
and quantification limits and accuracy were calculated.
The limit of detection (LOD) and limit of quantification
(LOQ) of the procedure are also shown in Table 1, which
were calculated according to the 3 s/m and 10 s/m
criterion, respectively, where s is the standard deviation
of the peak area ratios (n=4) of the sample and m is the
slope of the corresponding calibration curve.
The ruggedness and precision were checked on the
same and different days. The RSD % was calculated to
check the ruggedness and precision of the methods.
Accuracy was determined by recovery studies.
Procedure for Tablets
Ten tablets (Afebryl effervescent tablet, SMB
Technology, Belgium), labeled as containing 200 mg of
PAR, 300 mg of ACA and 300 mg AA, and excipients
were weighed and finely powdered. The average weight
per tablet was calculated from the weight of 10 tablets.
An accurate weight of the powder equivalent to one tablet
content was accurately weighed and transferred into 100
ml calibrated flask, diluted with mobile phase, stirred and
then made up to volume with the same solvent and
filtered. Appropriate volume of the filtered solution was
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taken in a 10 ml clean flask. Appropriate amount of
internal standard was added and diluted up to the mark
with the mobile phase.
Recovery Studies
To determine the accuracy, precision, reproducibility
and interference from excipients in the formulation,
recovery experiment of the above method was performed
from the laboratory made mixtures.
Drug analysis has been undertaken during various
phases of pharmaceutical development stages such as
formulation and stability studies, quality control and
pharmacological testing in animals and humans. All these
investigations require reliable and fully validated analytical
methods in order to determine active ingredients in
pharmaceutical formulations and biological samples.
In order to determine the effect of the simultaneous
elution of PAR, ACA, AA, SA and PCA peaks under
isocratic conditions, the mixtures of methanol and water
in different combinations, at different pH values and at
various flow rates were examined. The mixture of
methanol:water (35:65; v/v) adjusted to pH 3.1 with
-1
10% orthophosphoric acid at 1.8 ml min flow rate
proved to be better than the other mixtures and flow
rates for the separation since the chromatographic peaks
were observed to be better and without tailing.

Results
The precision and accuracy can often be enhanced by
the use of an appropriate internal standard, which also
serves to correct for fluctuations in the detector
response. Often, sample preparation steps that include
reaction, filtration, precipitation, extraction and so on
result in sample losses. When added prior to sample
preparation, a proper internal standard should be used to

Table 1. Results of system suitability.
Parameters

PAR

ACA

AA

SA

PCA

Resolution factor

5.86

5.47

3.88

3.36

10.53

Tailing factor

1.67

1.17

1.14

1.50

1.28

Selectivity

1.99

1.62

1.74

1.26

1.72

Capacity factor

2.33

7.26

1.34

9.15

12.36

RSD% of retention time

0.96

1.29

1.14

0.86

1.21

PAR: Paracetamol. ACA: Acetylsalicylic acid. AA: Ascorbic acid. SA: Salicylic acid. PCA: p-Chloroacetanilide. RSD: Relative standard deviation.
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5.00

13.357 PCA

8.123 SA

6.607 ACA

4.390 Smz

1.873 Ascorbic acid

2.657 Paracetamol

Detector response

correct for these losses. The maximum absorption for
acetaminophen was at 235 nm; therefore, this
wavelength was used throughout the analysis. The
internal standard is a different compound from the
analyte, but one that is well resolved in the separation.
The chemical structure of SMZ is not similar to the other
compound structures. However, it was chosen as the
internal standard because it showed a shorter retention
time with symmetrical peak and sharp and better
resolution compared to other potential internal
standards. SMZ did not interfere with the elution pattern
of the other agents. The selected conditions yielded
satisfactory chromatographic peak resolutions in a short
analysis time. The retention times were determined as
1.87 min for AA, 2.66 min for PAR, 6.6 min for ACA,
8.12 min for SA, 13.36 min for PCA and 4.39 min for
internal standard (SMZ) (Figure).

Time (min)

10.00

Figure. A typical chromatogram of an analysis of paracetamol (PAR),
acetylsalicylic acid (ACA), ascorbic acid (AA) and their
degradation and impurity products salicylic acid (SA) and pchloroacetanilide (PCA), and internal standard sulfamethoxazole
(SMZ).

Prior to the analysis of samples each day, the operator
must establish whether HPLC system and procedure are
capable of providing data of acceptable quality. This is
accomplished with system suitability experiments, which
can be defined as tests to ensure that the method can
generate results with acceptable accuracy and precision.
System suitability tests are used to verify that the
resolution and reproducibility of the chromatographic
system are adequate for the analysis. System suitability
tests were carried out according to United States
Pharmacopoeia (USP) 24, method <621> (29) on the
chromatogram of freshly prepared standard solutions to
check various parameters. These parameters included
relative standard deviations (RSD %) of retention times,
tailing factor, resolution, capacity factor, selectivity factor
and RSD % of peak height or area for repetitive injections
and are shown in Table 1. Typically, at least two of these
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criteria are required to demonstrate system suitability
tests were carried out using freshly prepared standard
stock solutions. As shown in Table 1, the method has
enabled good resolution factors of adjacent peaks, which
were greater than 1.0. The retention times in mobile
phase were used as hold-up time for the calculation of
capacity factor. The presented chromatographic
conditions ensure adequate retentions for all compounds,
since successful capacity factor values were obtained. The
results obtained from system suitability tests are in
agreement with the USP requirements.
Several approaches are given in the ICH guideline to
determine the detection (LOD) and quantification (LOQ)
limits (visual evaluation, signal-to-noise and standard
deviation of the response and the slope of the
corresponding calibration curve (LOD=3s/m; LOQ=10
s/m).
Peak area ratios (Asample / AIS) were plotted against
corresponding concentrations in the different
concentration ranges of the compounds. Linear
regression parameters of the peak area ratios versus
concentrations of the compounds are presented in Table
2. The results showed highly reproducible calibration
curves with correlation coefficients of >0.999. Necessary
statistical data of the regression equations such as LOD,
LOQ values, repeatability and reproducibility data are also
shown in Table 2. Repeatability and reproducibility were
characterized by RSD % (Table 2). According to these
results, there was no significant difference for the assay,
which was tested within day (repeatability) and between
days (reproducibility) (Table 2) (30,31). The proposed
method also demonstrates good precision, accuracy and
reproducibility, as shown in Table 2.
In order to demonstrate the validity and applicability
of the proposed HPLC method, recovery tests were
carried out by analyzing the synthetic mixtures of these
compounds, which were reproduced in different
composition ratios (Table 3). Recovery experiments using
the developed assay procedure further indicated the
absence of interference from commonly encountered
pharmaceutical excipients used in the selected formulation
and degradation product and impurity (Table 3).
The utility of the proposed method was verified by
means of replicate estimations of the marketed product
and results obtained were evaluated statistically (Table
4). It is concluded that the proposed method is
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Table 2. Results of least square regression analyses for the estimation of PAR, ACA, AA, SA and PCA using the proposed method.
Statistical Parameters
Linearity range (µg Ml-1)

PAR

ACA

AA

SA

PCA

0.5-4.0

0.75-6.0

0.75-6.0

1.0-12.0

1.0-12.0

Correlation coefficient

0.999

0.999

0.999

0.997

0.999

Slope

0.512

0.249

0.106

0.128

0.470

Intercept

0.010

-0.018

-0.02

0.041

0.033

SE of slope

0.0046

0.0026

0.0022

0.0060

0.011

SE of intercept

0.001

0.0098

0.0081

0.004

0.0076

LOD (µg mL-1)

0.036

0.048

0.130

0.107

0.038

LOQ (µg mL-1)

0.119

0.161

0.432

0.358

0.128

Repeatability (RSD %)

0.45

1.25

1.03

0.695

0.76

Reproducibility (RSD %)

0.56

1.61

1.44

1.45

0.86

PAR: Paracetamol. ACA: Acetylsalicylic acid. AA: Ascorbic acid. SA: Salicylic acid. PCA: p-Chloroacetanilide. LOD: Limit of detection. LOQ: Limit of
quantification. RSD: Relative standard deviation.

Table 3. Simultaneous determination of PAR, ACA and AA in the presence of their degradation products (SA and PCA) in laboratory-prepared
mixtures using the proposed method.
Compound

Concentration (µg Ml-1)

Amount Found* (µg Ml-1)

Recovery* %

RSD % of Recovery

20.0
30.0
30.0
2.0
2.0

20.00
29.98
29.96
1.987
1.996

100.0
99.93
99.87
99.35
99.80

0.72
0.40
0.60
0.10
0.25

PAR
ACA
AA
SA
PCA

PAR: Paracetamol. ACA: Acetylsalicylic acid. AA: Ascorbic acid. SA: Salicylic acid. PCA: p-Chloroacetanilide. RSD: Relative standard deviation.
* Each value is the mean of five experiments.

Table 4. Determination of PAR, ACA and AA in the presence of their degradation products (SA and PCA) in pharmaceutical dosage form using the
proposed method.
Compound

Labeled Claim (mg per tablet)

Amount Found %

RSD % of Amount Found

PAR
ACA
AA
SA
PCA

200.0
300.0
300.0
-

100.60
99.80
99.96
Not Detected
Not Detected

0.20
0.26
0.16
-

PAR: Paracetamol. ACA: Acetylsalicylic acid. AA: Ascorbic acid. SA: Salicylic acid. PCA: p-Chloroacetanilide. RSD: Relative standard deviation.

sufficiently accurate and precise for application to analysis
of pharmaceutical dosage forms.

Conclusion
In the present study, we have shown that our
proposed method using HPLC is convenient for

simultaneous detection of PAR, ASA, AA, SA and PCA.
The results of this reliable HPLC method demonstrate a
high level of precision and enough sensitivity for the
determination of all five compounds simultaneously. The
present HPLC method is simple, accurate and precise and
can be used for the determination of PAR, ACA, and AA
and possible degradation and impurity products in tablet
171
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dosage forms. Thus, this procedure can be easily adopted
for routine quality control analysis of tablet dosage forms
without any interference from the excipients or each
other.
Previously, several studies reported simultaneous
detection of PAR and ASA (32) and plus SA (33). PAR and
its impurity product PCA were also analyzed
simultaneously using HPLC (34). However, PAR and ASA

Turk J Med Sci

and their impurity products plus AA have not been
analyzed simultaneously until now. In some of the
analgesics, ASA and PAR exist together with AA.
Therefore, our proposed method for simultaneous
detection of these five substances is important for quality
control laboratories where economy and time are
essential.
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